Kronos Bio To Present Data At ACR Convergence 2024 To Support P300 KAT Inhibition As An Approach To Anti-Inflammatory Therapy
Kronos Bio To Present Data At ACR Convergence 2024 To Support P300 KAT Inhibition As An Approach To Anti-Inflammatory Therapy
Kronos Bio is exploring the utility of a p300 KAT inhibitor for autoimmune indications given the role of interferon regulatory factor 4 (IRF4) and p300 in B cells, T cells and other immune cells. The data being presented at the meeting support the role of p300 in inflammation, and the Company remains on track to announce a development candidate for autoimmune diseases by the end of 2024.– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases –
通過選擇性抑制促炎症轉錄，p300 KAt抑制劑調節驅動慢性炎症性疾病的多個促炎發佈信號通路的活性和功能
– Oral presentation taking place on Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST –
口頭報告將於2024年11月18日星期一下午4:15至4:30 EST舉行
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at the American College of Rheumatology's annual meeting, ACR Convergence 2024, being held from November 14 to 19, 2024 in Washington, DC.
加利福尼亞州聖馬特奧和馬薩諸塞州劍橋，2024年9月25日（環球新聞社）-- kronos bio公司（納斯達克：KRON），一家致力於開發針對由失調轉錄驅動的癌症和其他疾病的小分子治療藥物的公司，今日宣佈將於2024年11月14日至19日在華盛頓特區舉行的美國風溼病學會年會ACR Convergence 2024上，展示其針對自身免疫疾病的p300 KAt抑制劑項目的臨床前數據
Kronos Bio is exploring the utility of a p300 KAT inhibitor for autoimmune indications given the role of interferon regulatory factor 4 (IRF4) and p300 in B cells, T cells and other immune cells. The data being presented at the meeting support the role of p300 in inflammation, and the Company remains on track to announce a development candidate for autoimmune diseases by the end of 2024.
kronos bio正在探索利用p300 KAt抑制劑用於自身免疫疾病治療的可行性，考慮到干擾素調節因子4（IRF4）和p300在b細胞和其他免疫細胞中的作用。會議上發佈的數據支持p300在炎症中的作用，公司計劃在2024年底之前宣佈用於自身免疫疾病的開發候選藥物
譯文內容由第三人軟體翻譯。